Table 3. Meta-analysis results of the association between BIM deletion polymorphism and progression-free and overall survivals.
| Group |
Progression-free survival |
Overall survival |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| study(case) |
HR(95%CI) |
Adjusted HR (95%CI) |
study(case) |
HR(95%CI) |
Adjusted HR (95%CI) |
|||||
| Fixed | Random | Fixed | Random | Fixed | Random | Fixed | Random | |||
| NSCLC | 6 (839) | 2.000 (1.629–2.455) | 2.067 (1.591–2.685) | 2.194 (1.710–2.814) | 2.194 (1.710–2.814) | 2 (216) | 1.419 (0.893–2.256) | 1.361 (0.559–3.315) | — | — |
| HCC | 1 (89) | 0.720 (0.364–1.422) | 0.720 (0.364–1.422) | 0.866 (0.408–1.837) | 0.866 (0.408–1.837) | 1 (89) | 1.170 (0.740–1.850) | 1.170 (0.740–1.850) | 0.668 (0.300–1.500) | 0.668 (0.300–1.500) |
Abbreviation: NSCLC: non-small cell lung cancer; HCC: hepatocellular cancer; HR: hazard ratio; 95%CI: 95% confidential interval.